← Back to reports
Press release · May 2026
$3.434Bn2033 annual revenue, base-case pricing
9,1002033 annual treated patients (~27.6k cumulative)
12+Gene therapy programmes in active clinical development
2025–27Window for 5 pivotal readouts and 2 BLAs
Twelve gene therapies converge on retinitis pigmentosa as five pivotal readouts approach — Gene Scope forecasts a $3.4bn market by 2033.
London · 4 May 2026 · For immediate release
Retinitis pigmentosa (RP), the most common inherited retinal dystrophy, affects roughly 1 in 4,000 people — approximately 2 million globally and ~84,000 in the United States. Today, fewer than 1% of those patients have any disease-modifying option.
By 2033, that picture could change substantially: Gene Scope Intelligence projects approximately 9,100 RP patients treated with gene therapies in 2033 alone across 10 high-income markets (~27,600 cumulative through 2033), supporting 2033 annual revenues of approximately $3.434 billion under base-case pricing. A new MarketVIEW commercial opportunity assessment — covering the indication through to 2040 — quantifies that opportunity asset by asset, genotype by genotype, and market by market.
Key commercial thesis
RP now has the most active gene therapy pipeline in ophthalmology outside dry AMD.
Five pivotal or near-pivotal readouts and two BLA submissions converge in an 18-month window, with the first gene-agnostic Rolling BLA already underway. The strategic question is no longer whether gene therapy works in RP — it is which modality and which genotype captures share first, and at what price.
01 · The opportunity
A 99% unmet need — and an inflection point from 2026/27.
RP is genetically heterogeneous, with more than 200 disease-causing genes identified. Current management is supportive — low-vision aids, complication management, and genetic counselling.
Autosomal recessive forms predominate, alongside substantial autosomal dominant and X-linked subsets. Luxturna (voretigene neparvovec) remains the only approved gene therapy in the indication and reaches an estimated ~650 eligible biallelic-RPE65 patients in the U.S., leaving the remaining ~99% of RP patients without a disease-modifying option.
The catalyst calendar — 2025–2027
Five pivotal or near-pivotal readouts and at least two BLAs converge in an 18-month window.
Nanoscope MCO-010
Gene-agnostic optogenetic · Nanoscope Therapeutics
Rolling BLA initiated June 2025 — the first for a gene-agnostic retinal gene therapy — on the back of RESTORE Phase 2b/3 results showing ~3 lines of visual-acuity gain durable to three years.
Ocugen OCU400
Gene-agnostic modifier therapy · Ocugen
Phase 3 liMeliGhT (n=140) enrolment complete March 2026; topline Q1 2027; rolling BLA planned.
Beacon Therapeutics Laru-zova
X-linked RP · Beacon Therapeutics
Pivotal Phase 2/3 VISTA enrolment complete July 2025; topline H2 2026.
Janssen / J&J Bota-vec
X-linked RP · Janssen / Johnson & Johnson
Phase 3 LUMEOS missed its primary endpoint in May 2025, opening competitive space for Beacon, 4DMT, and others targeting the same genotype.
A second wave is building behind these: SparingVision's SPVN06 (PRODYGY neuroprotection, n=33 dosed) and SPVN20 (NYRVANA optogenetic, first patient October 2025); Ray Therapeutics' RTx-015 (FDA RMAT designation April 2026); 4DMT's 4D-125 in XLRP via intravitreal delivery; GenSight's optogenetic GS030 (PIONEER); PYC Therapeutics' VP-001 in PRPF31-associated RP advancing toward Phase 3; and Sepul Bio's ultevursen (Phase 2b LUNA, n=81) for USH2A-associated RP.
SparingVision SPVN06
SparingVision SPVN20
Ray Therapeutics RTx-015
4DMT 4D-125
GenSight GS030
PYC VP-001
Sepul Bio ultevursen
02 · What the report delivers
A patient-based forecast, built bottom-up.
A brand-new, patient-based commercial opportunity assessment forecasting gene therapy uptake and revenues in RP through 2040 across 10 high-income developed markets. Deliverables: an interactive Excel forecast model and a ~125-slide executive presentation.
Interactive Excel forecast model
Fully editable assumptions across epidemiology, diagnosis rate, disease-stage split, country-specific uptake curves, and pricing — buyers can stress-test the base case in minutes.
~125-slide executive presentation
Qualitative disease background, epidemiology, current treatment landscape, evolving R&D pipeline, and value-case discussion of healthcare costs potentially averted versus current standard of care.
Differentiating features
Built for stress-testing — not just summarising.
01
Disease-stage segmentation
Separate forecasts for early- to mid-stage and late-stage RP — the clinically meaningful split for differentiating asset positioning (e.g. MCO-010 in late-stage vs OCU400 in early- to mid-stage).
02
Four age-stratified cohorts
<18, 19–44, 45–64, ≥65 — built bottom-up from single-year-of-age country populations. Rare in syndicated forecasts and material for paediatric vs. adult pricing scenarios.
03
Three pricing scenarios per country
Low, Luxturna-anchored, and high — applied across all 10 markets and aggregated to global, North America, EU5 and developed RoW views.
04
Transparent, editable assumptions
Every input is exposed across epidemiology, diagnosis rate, disease-stage split, country-specific uptake curves (launch / medium-term / long-term), and pricing.
05
10-market geographic build-up
USA, Canada, France, Germany, Spain, Italy, UK, Australia, Japan and South Korea. North America accounts for ~50% of 2033 treated-patient volume and ~64% of 2033 revenue.
06
Annual forecast 2026–2040
Phased uptake curves capturing launch, medium-term, and long-term penetration dynamics. Auditable change-log with every quarterly refresh.
Plus qualitative analysis in the accompanying executive deck
Disease background, epidemiology, current treatment landscape, evolving R&D pipeline, and value-case discussion of healthcare costs potentially averted versus current standard of care.
03 · Who it is for
Built for decision-makers in ophthalmology gene therapy.
Designed around the live commercial questions teams in BD, corporate development, equity research, and payer modelling are working on right now.
BD & strategy
Business development and corporate strategy teams at ophthalmology-active pharma.
Corp dev
Corporate development at the named pipeline companies — competitive positioning and partnering economics.
Investors
Institutional investors with biotech ophthalmology positions and dedicated rare-disease equity mandates.
Payers
Payers modelling 2028+ budget impact for gene therapy in inherited retinal disease.
Licensing & disclaimer
Licensing — all rights reserved. This press release may be circulated freely. The underlying MarketVIEW report and forecast model are licensed separately. Gene Scope Intelligence is a trading brand of Assay Advantage Ltd (UK Company No. 5807728), publisher of Gene Scope Intelligence and sister brand to VacZine Analytics, a UK-based strategic research publisher operating since 2007.
Disclaimer. This press release is produced for informational and business development purposes only. All forecasts represent Gene Scope Intelligence's independent analytical judgement based on publicly available data and proprietary modelling as of Q2 2026. Nothing herein constitutes investment advice or a solicitation to invest. Clinical data referenced are from published or disclosed sources; Gene Scope Intelligence has no affiliation with any of the named companies. © 2026 Assay Advantage Ltd. All rights reserved.